Wordt geladen...
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
Clinical and preclinical data support a significant role for inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6 in the treatment of patients with breast cancer. Recently, based on data showing improvement in progression-free survival, the use of palbociclib (Ibrance; Pfizer, Inc.) in combinat...
Bewaard in:
| Gepubliceerd in: | Breast Care (Basel) |
|---|---|
| Hoofdauteurs: | , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
S. Karger GmbH
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4960359/ https://ncbi.nlm.nih.gov/pubmed/27493615 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000447284 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|